In a strategic bid to forge a global cannabis powerhouse, Curaleaf Holdings (TSX:CURA) unveiled its intention to launch a takeover bid for Aurora Cannabis (TSX/NASDAQ:ACB). The proposed offer values Aurora at US$4 per share —reflecting a 45% premium over its 30-day volume-weighted average price (VWAP)— with potential upside capped at US$5 per share (an 82% premium) under a structured cash-and-stock arrangement.
The decision to go public follows multiple unsuccessful attempts by Curaleaf to negotiate privately with Aurora’s board, according to company statements.
Strategic rationale and market impact
If completed, the combined enterprise would rank among the world’s most diversified and highest-grossing cannabis operations. Key drivers behind the proposed consolidation include:
- Unmatched international reach: The entity would establish a footprint spanning 17 countries, anchored by European and North American EU-GMP manufacturing infrastructure.
- Formidable financial scale: On a combined basis, the two businesses generated over US$1.5 billion in revenue and nearly US$350 million in adjusted EBITDA over the trailing twelve months.
- Operational synergies: Curaleaf projects a minimum of US$40 million in annual cost savings, with additional upside from integrating its genetics portfolio into Aurora’s manufacturing capacity.
- U.S. market exposure for Aurora investors: Aurora shareholders would gain direct upside to Curaleaf’s dominant position across key U.S. markets —a major advantage as potential federal regulatory shifts loom.
Regulatory roadmap
The offer remains subject to formal filings with both Canadian securities regulators and the U.S. Securities and Exchange Commission (SEC), after which official documentation will be dispatched to Aurora shareholders.
Leadership commentary
“We believe this combination represents a win-win for Curaleaf and Aurora shareholders. We are offering Aurora shareholders a unique opportunity to participate in a more highly diversified global platform and increase their exposure to US regulatory tailwinds,” Boris Jordan, Chair and Chief Executive Officer of Curaleaf, said in a statement. “By combining Curaleaf’s global distribution platform with Aurora’s leading international medical cannabis franchise and EU-GMP cultivation and manufacturing capacity, we see significant potential to unlock value through substantial cost and revenue synergies.”
“We approached Aurora privately and constructively on multiple occasion,” Jordan added. “We were very disappointed that the board refused to meaningfully engage. We will now take our proposal directly to Aurora shareholders because the premium is significant, the strategic rationale is compelling and further delay is unjustified. Curaleaf remains ready to engage constructively with Aurora’s board to advance this value-maximizing transaction, and we are prepared to move quickly towards a definitive agreement.”
About Curaleaf Holdings
Curaleaf is a top international cannabis consumer products provider. Its brand portfolio includes Curaleaf, Select, Grassroots, Find, Anthem and Dark Heart.
Curaleaf stock (TSX:CURA) is up by 1.30 per cent on the news, trading at C$13.25 as of 12:41 pm ET. The stock has added 16.23 per cent year-over-year.
About Aurora Cannabis
Aurora Cannabis is a top medical cannabis company serving markets in Canada, Europe, Australia and New Zealand. Its brand portfoio includes Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corporation.
Aurora Cannabis stock (TSX/NASDAQ:ACB) is up by 20.59 per cent on the news, trading at US$3.48 as of 11:57 am ET. The stock has given back 33.11 per cent year-over-year.